Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q2 EPS

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• MSC Industrial (MSM) PT Raised to $130 at Jefferies
• Bassett Furniture Industries (BSET) Tops Q2 EPS by 1c, Misses on Revenue